CVACCureVac N.V.

Nasdaq curevac.com


$ 4.69 $ -0.16 (-3.3 %)    

Friday, 07-Jun-2024 10:08:46 EDT
QQQ $ 462.89 $ 1.34 (0.29 %)
DIA $ 389.43 $ 0.10 (0.03 %)
SPY $ 534.26 $ 0.94 (0.18 %)
TLT $ 91.54 $ -0.08 (-0.09 %)
GLD $ 214.09 $ -0.20 (-0.1 %)
$ 4.99
$ 4.85
$ 0.00 x 0
$ 4.66 x 100
$ 4.61 - $ 4.85
$ 2.22 - $ 12.36
3,875,277
na
1.12B
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 first-human-death-from-bird-flu-strain-puts-vaccine-stocks-back-on-the-map

Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.

Core News & Articles

https://globalnews.ca/news/10547712/bird-flu-death-mexico-h5n2/#:~:text=It%20started%20on%20April%2017,to%20complications%20of%...

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 covid-19-patent-dispute-sorted-acuitas-therapeutics-and-curevac-reach-settlement-in-patent-battle

Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfi...

 leerink-partners-downgrades-curevac-to-market-perform-lowers-price-target-to-4

Leerink Partners analyst Mani Foroohar downgrades CureVac (NASDAQ:CVAC) from Outperform to Market Perform and lowers the pri...

Core News & Articles

https://www.curevac.com/en/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-collabora...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION